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Thailand Thumbs Nose at USTR, Makes Affordable AIDS Treatment Top
Priority
By Greg Lultschik
This piece was originally featured as a blog post at www.ipbrief.net. The AU Intellectual
Property Brief provides daily content on hot issues, breaking news, and trends within
intellectual property law worldwide.
Thailand is making waves on the international patent
scene again with its plans to extend compulsory licensing
schemes for Sustiva and Kaletra, two important HIV/
AIDS drugs. With Thailand being a familiar face on the
USTR’s 301 report and its prior scrap over this licensing
plan with Kaletra owner Abbot Laboratories, the country seems to be willing to thumb its nose at the Trade
Representative and the pharma giant’s significant influence. The decision came down after the Disease Control
Department, the Department of Intellectual Property, the Foreign Ministry,
the Government Pharmaceutical Organization, the FDA,
and several AIDS activist
organizations agreed that the
compulsory licensing policy
was in accordance with the
2001 Doha Declaration. For
that many groups to reach
a mutual agreement, my
guess is that either some very
good coffee was served at the
meeting or that the representatives were told that lunch
was conditional upon their
reaching a conclusion.
In effect, the decision allows
the Thai government to continue importing generic
versions of the two drugs from India. With savings on
AIDS drugs standing at $36 million since the licenses
were imposed and $100 million in potential savings if
the licenses are extended for the duration of the patents,
the decision whether to maintain this policy has serious
implications for access to HIV/AIDS treatment in Thailand. With the licenses in place, approximately 29,360
people are receiving Sustiva and 6,200 have access to
Kaletra. Before, only 4,539 people could get Sustiva

and 39 could afford Kaletra. Yes, that’s 39 people out of
a nation with an HIV+ population of almost 610,000.
(http://www.bangkokpost.com/news/health/189154/
hiv-aids-drugs-licence-extended)
Some WCL students know that you can’t string together
the words “Doha,” “Pharmaceuticals,” and “301 report”
without attracting the attention of Professor Flynn over
at the Program on Information Justice and Intellectual
Property (PIJIP). Professor Flynn and PIJIP
covered this compulsory
licensing issue extensively back in 2007, and the
reports are still available
here. For some other PIJIP work on the Special
301 report and access to
medicines, check out the
links below.
Review of the 2010
Special 301 Report Sections on IP and Access to
Medicines
http://www.wcl.
american.edu/pijip/go/
blog-post/preliminaryreview-of-the-2010-special-301-report-sections-on-ip-and-access-to-medicines
PIJIP Calls for USTR Policy Change to Promote Access
to Medicines:
http://www.wcl.american.edu/pijip/go/pijip03022010
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